Filing Details

Accession Number:
0001567619-21-011842
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-06-08 17:11:36
Reporting Period:
2021-06-06
Accepted Time:
2021-06-08 17:11:36
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1512762 Coherus Biosciences Inc. CHRS () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1420822 M Dennis Lanfear Coherus Biosciences, Inc.
333 Twin Dolphin Drive, Suite 600
Redwood City CA 94065
President & Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-06-06 300,000 $0.42 493,258 No 4 M Direct
Common Stock Acquisiton 2021-06-08 31,054 $0.42 524,312 No 4 M Direct
Common Stock Disposition 2021-06-08 31,054 $13.56 493,258 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2021-06-06 300,000 $0.00 300,000 $0.42
Common Stock Stock Option (Right to Buy) Disposition 2021-06-08 31,054 $0.00 31,054 $0.42
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
31,054 2021-07-17 No 4 M Direct
0 2021-07-17 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 446,684 Indirect By Trust
Common Stock 86,965 Indirect By LLC
Footnotes
  1. These shares are held by the Lanfear Revocable Trust, dated January 27, 2004, as restated, of which Reporting Person is a trustee.
  2. These shares are held by Lanfear Capital Advisors, LLC of which Reporting Person is President.
  3. The transaction was executed in multiple trades in prices ranging from $13.55 to $13.61, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
  4. The shares underlying this option are fully vested and exercisable as of the date hereof.